← Back to headlines
UCB's Bimzelx Outperforms AbbVie's Skyrizi in Psoriatic Arthritis Trial
UCB announced that its drug Bimzelx demonstrated superior efficacy compared to AbbVie's Skyrizi in a clinical trial for psoriatic arthritis.
19 May, 13:52 — 19 May, 13:52
Sources
Showing 1 of 1 sources
